Upcoming Research Study "India Biosimilar Market Analysis" Highlights Billion Dollar Opportunity for Biosimilar Drugs Development & Marketing in India

Delhi, India, August 09, 2012 --(PR.com)-- According to an upcoming research study “India Biosimilar Market Analysis” by KuicK Research, there exist phenomenal growth opportunities for development and marketing of Biosimilar drugs in India. India is one of the biggest sources of biosimilars and is also an emerging market with its billion populations and investment in technology. The biosimilars market in India is driven by several factors including an increase in disease prevalence resulting from population growth, old age and unhealthy lifestyles, the need for broader access to medicines, increasing healthcare costs and the increasing demand for cheaper drugs, cost-effectiveness of biosimilars in comparison to their expensive counterparts, reduced risk of pipeline failure coupled with higher acceptability by patients, impending patent expiries of major biotechnology drugs, and the fast regulatory process for approval of biosimilars.

The report gives detailed insight on the various aspects related to the biosimilar market in India and its future growth opportunities in terms of domestic sales, biosimilar pipeline analysis, recently announced regulatory and approval process for development and marketing of biosimilars, partnerships for the development of biosimilar drugs and detailed information on expiry of patent drugs till 2015.

Report Table of Contents
1. India Biosimilar Market Overview
2. Indian Market for Biosimilar by Drug Class
3. Biosimilar Pipeline Analysis
4. Factors Driving the Market
4.1 Regulatory Framework for Biosimilar Drug
4.2 Cost Advantage of Biosimilar Development
4.3 Biologics Patent Expiration
4.4 Cost Saving to Healthcare System
5. Indian Regulatory Framework for Biosimilar Drugs in India
5.1 Competent Authorities For Approval Process
5.2 Principles for Development of Biosimilar
5.3 Preclinical Studies
5.4 Clinical Trial Application
5.5 Market Authorization Application
5.6 Post-Market Data for Biosimilar
6. Biosimilar Development Capabilities of Indian Players and their Partnerships and Acquisitions
6.1 Mergers & Acquisitions
6.2 Development & Marketing Partnership
6.2.1 Dr. Reddy’s Laboratories & Merck Serono
6.2.2 Biocon & Mylan Inc
6.2.3 Ranbaxy & Pfenex
7. Future of Indian Biosimilar Market
7.1 Domestic Market Expansion
7.2 Contract Manufacturing Opportunity
8. Indian Biosimilar Drugs to Enter the US & European Market
9. Competitive Landscape
9.1 Dr.Reddy's Labs (DRL)
9.2 Intas Pharmaceuticals Ltd.
9.3 Biocon Limited
9.4 Wockhardt Limited
9.5 Shantha Biotechnics Limited
9.6 Reliance Life Sciences
9.7 Cipla

For more information please contact them at info@kuickresearch.com